Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab

Breast

Volumn 25, Issue , 2016, Pages 22-26

  Tonyali, Onder ^a   Coskun, Ugur ^b   Yuksel, Sinemis ^c   Inanc, Mevlude ^d   Bal, Oznur ^e   Akman, Tulay ^f   Yazilitas, Dogan ^g   Ulas, Arife ^h   Kucukoner, Mehmet ⁱ   Aksoy, Asude ^j   Demirci, Umut ^k   Uysal, Mukremin ^l   Tanriverdi, Ozgur ^m   Gunaydin, Yusuf ^b   Sumbul, Ahmet Taner ^a   Yildiz, Ramazan ^c   Karaca, Halit ^d   Oksuzoglu, Berna ^e   Ciltas, Aydin ^b   Buyukberber, Suleyman ^b   Benekli, Mustafa ^b   more..

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

^c DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^d ERCIYES UNIVERSITY   (Turkey)

^e ANKARA ONCOLOGY EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^f DOKUZ EYLUL UNIVERSITY   (Turkey)

^g Konya Numune Education and Research Hospital   (Turkey)

^h Ali Osman Sonmez Oncology Hospital   (Turkey)

ⁱ DICLE UNIVERSITY   (Turkey)

^j INONU UNIVERSITY   (Turkey)

^k ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^l AFYON KOCATEPE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^m MUGLA SITKI KOCMAN UNIVERSITY   (Turkey)

more..

Author keywords

Adjuvant therapy; Brain metastasis; Breast cancer; Trastuzumab

Indexed keywords

TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; COHORT ANALYSIS; COMPETING RISKS REGRESSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HER2 POSITIVE EARLY STAGE BREAST CANCER; HORMONAL THERAPY; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENT DISEASE; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TUMOR CLASSIFICATION; ADJUVANT CHEMOTHERAPY; BRAIN NEOPLASMS; BREAST NEOPLASMS; CHEMISTRY; CLINICAL TRIAL; INCIDENCE; MASTECTOMY; MIDDLE AGED; MULTICENTER STUDY; PARTIAL MASTECTOMY; PATHOLOGY; SECONDARY; STATISTICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; MASTECTOMY; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; RISK FACTORS; TRASTUZUMAB; YOUNG ADULT;

EID: 84959084796     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2015.11.006     Document Type: Article

References (28)

1. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137.
2. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
3. Gianni L., Dafni U., Gelber R.D., Azambuja E., Muehlbauer S., Goldhirsch A., et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011, 12:236-244.
4. Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011, 365:1273-1283.
5. Perez E.A., Romond E.H., Suman V.J., Jeong J.H., Davidson N.E., Geyer C.E., et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011, 29:3366-3373.
6. Boekhout A.H., Beijnen J.H., Schellens J.H. Trastuzumab. Oncologist 2011, 16:800-810.
7. Pivot X., Romieu G., Debled M., Pierga J.Y., Kerbrat P., Bachelot T., et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol 2013, 14:741-748.
8. Tonyali O., Coskun U., Sener N., Inanc M., Akman T., Ulas A., et al. Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab. Onkologie 2013, 36:554-558.
9. Chien A.J., Rugo H.S. Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2013, 137:1-12.
10. Weil R.J., Palmieri D.C., Bronder J.L., Stark A.M., Steeg P.S. Breast cancer metastasis to the central nervous system. Am J Pathol 2005, 167:913-920.
11. Brufsky A.M., Mayer M., Rugo H.S., Kaufman P.A., Tan-Chiu E., Tripathy D., et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 2011, 17:4834-4843.
12. Pestalozzi B.C., Zahrieh D., Price K.N., Holmberg S.B., Lindtner J., Collins J., et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006, 17:935-944.
13. Spielmann M., Roché H., Delozier T., Canon J.L., Romieu G., Bourgeois H., et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009, 27:6129-6134.
14. Perez E.A., Suman V.J., Davidson N.E., Gralow J.R., Kaufman P.A., Visscher D.W., et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 2011, 29:4491-4497.
15. Olson E.M., Abdel-Rasoul M., Maly J., Wu C.S., Lin N.U., Shapiro C.L. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Ann Oncol 2013, 24:1526-1533.
16. Bria E., Cuppone F., Fornier M., Nisticò C., Carlini P., Milella M., et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat 2008, 109:231-239.
17. Viani G.A., Afonso S.L., Stefano E.J., De Fendi L.I., Soares F.V. Adjuvant trastuzumab in the treatment of HER-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 2007, 7:153.
18. Dahabreh I.J., Linardou H., Siannis F., Fountzilas G., Murray S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 2008, 13:620-630.
19. Burstein H.J., Lieberman G., Slamon D.J., Winer E.P., Klein P. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 2005, 16:1772-1777.
20. Clayton A.J., Danson S., Jolly S., Ryder W.D., Burt P.S., Stewart A.L., et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004, 91:639-643.
21. Bendell J.C., Domchek S.M., Burstein H.J., Harris L., Younger J., Kuter I., et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003, 97:2972-2977.
22. Pestalozzi B.C., Holmes E., de Azambuja E., Metzger-Filho O., Hogge L., Scullion M., et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol 2013, 14:244-248.
23. Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 2009, 27:5278-5286.
24. Vaz-Luis I., Ottesen R.A., Hughes M.E., Marcom P.K., Moy B., Rugo H.S., et al. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res 2012, 14:R129.
25. Musolino A., Ciccolallo L., Panebianco M., Fontana E., Zanoni D., Bozzetti C., et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer 2011, 117:1837-1846.
26. Vaz-Luis I., Winer E.P., Lin N.U. Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?. Ann Oncol 2013, 24:283-291.
27. Kennecke H., Yerushalmi R., Woods R., Cheang M.C., Voduc D., Speers C.H., et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010, 28:3271-3277.
28. Niwińska A., Tacikowska M., Murawska M. The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death. Int J Radiat Oncol Biol Phys 2010, 77:1134-1139.